[Therapeutic effects of secondary antitubercular agents at our hospital]. 1966

K Nakayama, and M Hayashida, and M Ishihara, and F Ijichi, and Y Obata

UI MeSH Term Description Entries
D007612 Kanamycin Antibiotic complex produced by Streptomyces kanamyceticus from Japanese soil. Comprises 3 components: kanamycin A, the major component, and kanamycins B and C, the minor components. Kanamycin A,Kanamycin Sulfate,Kantrex
D003523 Cycloserine Antibiotic substance produced by Streptomyces garyphalus. R-4-Amino-3-isoxazolidinone,Seromycin
D004352 Drug Resistance, Microbial The ability of microorganisms, especially bacteria, to resist or to become tolerant to chemotherapeutic agents, antimicrobial agents, or antibiotics. This resistance may be acquired through gene mutation or foreign DNA in transmissible plasmids (R FACTORS). Antibiotic Resistance,Antibiotic Resistance, Microbial,Antimicrobial Resistance, Drug,Antimicrobial Drug Resistance,Antimicrobial Drug Resistances,Antimicrobial Resistances, Drug,Drug Antimicrobial Resistance,Drug Antimicrobial Resistances,Drug Resistances, Microbial,Resistance, Antibiotic,Resistance, Drug Antimicrobial,Resistances, Drug Antimicrobial
D005000 Ethionamide A second-line antitubercular agent that inhibits mycolic acid synthesis. Amidazine,Ethioniamide,Trecator,Trecator-SC,Trecator SC
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000995 Antitubercular Agents Drugs used in the treatment of tuberculosis. They are divided into two main classes: "first-line" agents, those with the greatest efficacy and acceptable degrees of toxicity used successfully in the great majority of cases; and "second-line" drugs used in drug-resistant cases or those in which some other patient-related condition has compromised the effectiveness of primary therapy. Anti-Tuberculosis Agent,Anti-Tuberculosis Agents,Anti-Tuberculosis Drug,Anti-Tuberculosis Drugs,Antitubercular Agent,Antitubercular Drug,Tuberculostatic Agent,Tuberculostatic Agents,Antitubercular Drugs,Agent, Anti-Tuberculosis,Agent, Antitubercular,Agent, Tuberculostatic,Anti Tuberculosis Agent,Anti Tuberculosis Agents,Anti Tuberculosis Drug,Anti Tuberculosis Drugs,Drug, Anti-Tuberculosis,Drug, Antitubercular
D014397 Tuberculosis, Pulmonary MYCOBACTERIUM infections of the lung. Pulmonary Consumption,Pulmonary Phthisis,Pulmonary Tuberculoses,Pulmonary Tuberculosis,Tuberculoses, Pulmonary,Consumption, Pulmonary,Consumptions, Pulmonary,Phthises, Pulmonary,Phthisis, Pulmonary,Pulmonary Consumptions,Pulmonary Phthises

Related Publications

K Nakayama, and M Hayashida, and M Ishihara, and F Ijichi, and Y Obata
March 1966, Iryo,
K Nakayama, and M Hayashida, and M Ishihara, and F Ijichi, and Y Obata
January 1963, Tuberkuloza,
K Nakayama, and M Hayashida, and M Ishihara, and F Ijichi, and Y Obata
January 1966, Saishin igaku. Modern medicine,
K Nakayama, and M Hayashida, and M Ishihara, and F Ijichi, and Y Obata
July 1963, Orvosi hetilap,
K Nakayama, and M Hayashida, and M Ishihara, and F Ijichi, and Y Obata
May 1968, Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke,
K Nakayama, and M Hayashida, and M Ishihara, and F Ijichi, and Y Obata
January 1966, Saishin igaku. Modern medicine,
K Nakayama, and M Hayashida, and M Ishihara, and F Ijichi, and Y Obata
January 1971, Ceskoslovenska oftalmologie,
K Nakayama, and M Hayashida, and M Ishihara, and F Ijichi, and Y Obata
March 1968, Kekkaku : [Tuberculosis],
K Nakayama, and M Hayashida, and M Ishihara, and F Ijichi, and Y Obata
February 1998, La Tunisie medicale,
K Nakayama, and M Hayashida, and M Ishihara, and F Ijichi, and Y Obata
December 1985, Zhonghua jie he he hu xi xi ji bing za zhi = Chinese journal of tuberculosis and respiratory diseases,
Copied contents to your clipboard!